scholarly journals Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma

2022 ◽  
Author(s):  
Andrew J. Woerner ◽  
Guy E. Johnson
Keyword(s):  
Hepatocellular Carcinoma ◽  
Recent Advances ◽  
Treatment Considerations ◽  
Treatment Paradigm ◽  
Yttrium 90 ◽  
Related Mortality

Hepatocellular carcinoma remains a prominent cause of cancer-related mortality globally. Transarterial yttrium-90 radioembolization is a versatile therapy and plays an important role in the treatment of hepatocellular carcinoma. This review summarizes the establishment of radioembolization in the hepatocellular carcinoma treatment paradigm, treatment considerations across cancer stages, and recent advances in evidence.

Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances

2016 ◽  
Vol 11 (3) ◽  
pp. 238-252
Author(s):  
Giovanni Galati ◽  
Chiara Dell'Unto ◽  
Umberto Vespasiani-Gentilucci ◽  
Antonio De Vincentis ◽  
Paolo Gallo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Alcoholic Liver Disease ◽  
Current Management ◽  
Recent Advances

Measuring radiation exposure of operators engaged in the yttrium-90 microsphere radioembolization treatment of hepatocellular carcinoma patients

Optik ◽  
2021 ◽  
pp. 167392
Author(s):  
Jina Shim ◽  
Gyoung Min Kim ◽  
Do Young Kim ◽  
Mi Jin Yun ◽  
Soo Hyun Seo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Exposure ◽  
Yttrium 90

scholarly journals Pathologic validation of an yttrium-90 trans-arterial radioembolization dosimetry: a case report

2021 ◽  
Vol 2021 (4) ◽  
Author(s):  
Jacqueline B Baikovitz ◽  
Lindsay Thornton ◽  
Monica T Garcia-Buitrago ◽  
Alan S Livingstone ◽  
Matthew T Studenski ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Liver Resection ◽  
Pathologic Response ◽  
Clinical Scenario ◽  
Complete Pathologic Response ◽  
Pathological Findings ◽  
Rigorous Approach ◽  
Yttrium 90

Abstract Yttrium-90 (Y-90) trans-arterial radioembolization (TARE) is used in the management of unresectable hepatocellular carcinoma (HCC). During the last 5 years, dosimetry software has been developed to allow for a more rigorous approach of dose prescription in Y-90 TARE. We present here a case study of a 77-year-old woman diagnosed with HCC, who underwent a Y-90 TARE as a bridge procedure to liver resection. This clinical scenario represents a unique opportunity to illustrate the predictive value of dosimetric findings correlating dosimetry with pathological findings. In this case, Y-90 TARE dosimetry was predictive of treatment response in which the tumor received a mean dose of 156 Gy and demonstrated a complete pathologic response.

scholarly journals Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma

2016 ◽  
Vol 33 (5) ◽  
pp. 699-714 ◽  
Author(s):  
Joseph Ralph Kallini ◽  
Ahmed Gabr ◽  
Riad Salem ◽  
Robert J. Lewandowski
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Radioembolization ◽  
Yttrium 90
Sign in / Sign up

Export Citation Format

Share Document